EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair

Gabison, Éric; Hoang–Xuan, T.; Mauviel, Alain; Ménashi, Suzanne

doi:10.1016/j.biochi.2004.09.023

Cited by 258 publications

(245 citation statements)

References 54 publications

Supporting

Mentioning

234

Contrasting

Unclassified

Order By: Relevance

“…In this line of investigation, Takata and colleagues [9] observed that SLC16A3 (solute carrier family 16 -monocarboxylic acid transporter 4 -MCT4, member 3) is up-regulated in patients that do not respond to neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) therapy. SLC16A3 (MCT4) is closely associated with CD147 [10], a highly glycosylated cell surface transmembrane protein which stimulates matrix metalloproteinases synthesis and angiogenesis in tumour local environment [11]. CD147 seems to be related with cisplatin resistance of bladder cancer [12].…”

Section: Introductionmentioning

confidence: 99%

CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis

Afonso

Longatto‐Filho

Baltazar

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Background Urothelial bladder carcinoma (UBC) is a chemo-sensitive tumour, but the response to treatment is heterogeneous. CD147 has been associated with chemotherapy resistance. We aimed to define tumours with an aggressive phenotype by the combined analysis of clinicopathological and biological parameters.Methods 77 patients with T1G3 or muscle-invasive UBC treated by radical cystectomy were studied. Immunohistochemistry was performed to detect CD147, heparanase, CD31 (blood vessels identification) and D2-40 (lymphatic vessels identification) expressions. The immunohistochemical reactions were correlated with the clinicopathological and the outcome parameters. 5-year disease free survival (DFS) and overall survival (OS) rates were estimated using the Kaplan-Meier method. Multivariate analysis was performed by Cox proportional hazards analysis. ResultsThe 5-year DFS and OS rates were significantly influenced by the classical clinicopathological parameters, and by the occurrence of lymphovascular invasion.CD147 and heparanase immunoexpression did not affect patients' outcome. However, patients with pT3/pT4 tumours had a median OS time of 14.7 months (95% CI 7.1-22.3, p=0.003), which was reduced to 9.2 months (95% CI 1.5-17.0, p=0.008) if the tumours were CD147 positive. We developed a model of tumour aggressiveness using parameters as stage, grade, lymphovascular invasion and CD147 immunoexpression, which separated a low aggressiveness from a high aggressiveness group, remaining as an independent prognostic factor of DFS (HR 3.746; p=0.019) and OS (HR 3.247; 95% CI 1.015-10.388, p=0.047).Conclusion CD147 overexpression, included in a model of UBC aggressiveness, may help surgeons to identify patients who could benefit from a personalized therapeutic regimen. Additional validation is needed.

show abstract

Section: Introductionmentioning

confidence: 99%

CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis

Afonso

Longatto‐Filho

Baltazar

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…CD147 is a cellular adhesion molecule involved in cell-cell and cellextracellular matrix interactions. It can stimulate MMP production but does not affect the production of tissue inhibitor of metalloproteinases, the physiologic inhibitors for MMPs, hence modifying the collagenolytic balance toward MMP activation (6). CD147 expression is elevated on several human tumors and has been correlated with the malignancy in some cancers such as primary breast cancer and ovarian cancer, etc.…”

Section: Introductionmentioning

confidence: 99%

HAb18G/CD147 Functions in Invasion and Metastasis of Hepatocellular Carcinoma

Xu¹,

Xu²,

Zhang³

et al. 2007

Molecular Cancer Research

144

134

View full text Add to dashboard Cite

CD147 molecule is reported to be correlated with the malignancy of some cancers; however, it remains unclear whether it is involved in the progression of hepatocellular carcinoma (HCC). Here, we investigated the function of HAb18G/CD147, a member of CD147 family, and its antibodies, HAb18 and LICARTIN, in HCC invasion and metastasis. We observed that HAb18G/CD147 gene silence in HCC cells significantly decreased the secretion of matrix metalloproteinase (MMP) and the invasive potential of HCC cells (P < 0.001). MMP silence in HCC cells also significantly suppressed the invasion of the cells when cocultured with fibroblasts; however, its inhibitory effect was significantly weaker than that of both HAb18G/CD147 silence in HCC cells and that of MMP silence in fibroblasts (P < 0.001). Blocking the HAb18G/CD147 molecule on HCC cells with HAb18 monoclonal antibody resulted in a similar suppressive effect on MMP secretion and cell invasion, but with no significant effects on the cell growth. 131 I-labeled HAb18 F(ab ¶) 2 (LICARTIN), however, significantly inhibited the in vitro growth of HCC cells (P < 0.001). In an orthotopic model of HCC in nude mice, HAb18 and LICARTIN treatment effectively reduced the tumor growth and metastasis as well as the expression of three major factors in the HCC microenviroment (MMPs, vascular endothelial growth factor, and fibroblast surface protein) in the paracancer tissues. Overall, these results suggest that HAb18G/CD147 plays an important role in HCC invasion and metastasis mainly via modulating fibroblasts, as well as HCC cells themselves to disrupt the HCC microenviroment. LICARTIN can be used as a drug targeting to HAb18G/ CD147 in antimetastasis and recurrence therapy of HCC.

show abstract

“…CD147 has been implicated inmany pathological processes, such as rheumatoid arthritis,experimental lung injury, atherosclerosis, chronic liverdisease induced by hepatitis C virus, ischemic myocardial injury and heart failure (12). Treatment of transplant patientswith a CD147 antibody was effective due to inhibition of T-cell activation (14).…”

Section: Treatment [Table 14] Cd147 (Emmprin)mentioning

confidence: 99%

Scd147: Emmprin(extracellular Matrix Metalloprotienase Inducer) as Tumour Marker for Bladder Carcinoma.

mujtaba.¹,

malik.²,

shah.³

et al. 2017

IJAR

View full text Add to dashboard Cite

Bladder cancer is the second most common cancer of the genitourinary tract. It accounts for 7% of new cancer cases in men and 2% of new cancer cases in women. The incidence is higher in whites than in African Americans, and there is a positive social class gradient for bladder cancer in both sexes. The average age at diagnosis is 65 years, with approximately 75% of bladder cancers are localized to the bladder, 25% have spread to regional lymph nodes or distant sites. A detailed study of bladder cancer cases registered from 2005 to 2010 in our tertiary care hospital revealed that bladder cancer ranks as the 7 th leading cancer and 5.9% of all prevalent cancers in the Kashmiri population(1). TNM Staging System:-The TNM staging system is the most commonly used system. Table 13 (a and b) Clinical features:-Hematuria (painless) is the presenting symptom in 85-90% of patients with bladder cancer. It may be gross or microscopic, intermittent rather than constant. In a smaller percentage of patients, it is accompanied by symptoms of vesical irritability: frequency, urgency, and dysuria. Irritative voiding symptoms seem to be more common in patients with diffuse CIS. Symptoms of advanced disease include bone pain from bone metastases or flank pain from retroperitoneal metastases or ureteral obstruction.Patients with large-volume or invasive tumors may be found to have bladder wall thickening or a palpable mass-findings that may be detected on a careful bimanual examination under anesthesia. Hepatomegaly and supraclavicular lymphadenopathy are signs of metastatic disease. Lymphedema from occlusive pelvic lymphadenopathy may be seen occasionally. The most common laboratory abnormality is hematuria. It may be accompanied by pyuria, which on occasion may result from concomitant urinary tract infection.Currently, urine cytology is the standard non-invasive marker. In a recent literature reviews, specificity of cytology ranged from 83% to 99.7% with a mean ± standard deviation (SD) of 99% and sensitivity ranged from 20% to 53% with a mean ± SD of 34%(02).Other tumor markers. i. ImmunoCyt/uCyt+ test . ii. BTA TRAK Assay . iii. BTA Stat Test .

show abstract

EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair

Cited by 258 publications

References 54 publications

CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis

CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis

HAb18G/CD147 Functions in Invasion and Metastasis of Hepatocellular Carcinoma

Scd147: Emmprin(extracellular Matrix Metalloprotienase Inducer) as Tumour Marker for Bladder Carcinoma.

Contact Info

Product

Resources

About